Advertisement

HMG-CoA reductase expression in human eyelid tissue and in a human meibomian gland epithelial cell line

  • Kenneth G-J OoiEmail author
  • Anupam Rao
  • Jonathan S-K Goh
  • Gary Gracie
  • Svetlana Cherepanoff
  • Michele C. Madigan
  • Stephanie L. Watson
Basic Science
  • 36 Downloads

Abstract

Purpose

3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), the rate-limiting enzyme of cholesterol production, has been found to contribute to lipid secretion from skin sebaceous glands and hair follicles. We assessed for HMGCR expression in human eyelid tissue and in immortalized human meibomian gland epithelial cells (HMGECs) using immunohistochemistry.

Methods

Full thickness human eyelid specimens in archival paraffin blocks were obtained. A section from each block was stained with hematoxylin and eosin and examined by an ocular pathologist for validation of tissue pathology. Immunohistochemistry was performed using rabbit anti-human HMGCR antibody on serial sections using the Ventana automated staining system. HMGCR expression was examined for in HMEGCs with fluorescence immunocytochemistry and confocal microscopy.

Results

Thirteen full thickness eyelid specimens met the inclusion criteria. All specimens contained meibomian glands, and 2 (15%) contained glands of Zeis, 3 (23%) pilosebaceous glands, 2 (15%), accessory lacrimal glands, and 2 (15%), glands of Moll, respectively. Immunohistochemistry showed HMGCR expression in meibocytes of meibomian glands and sebocytes of Zeis and pilosebaceous glands in all specimens. HMGCR expression was also evident in vascular endothelium. Immunofluorescence was positive for HMGCR expression on HMGEC cells. No labeling was seen for the negative Ig control.

Conclusion

HMGCR was expressed in all eyelid sebaceous-type glands and in HMGECs, consistent with a role for cholesterol production in the genesis of tear film lipids. The observed expression also provides a rationale for using topical statins, inhibitors of HMGCR, as novel tear film lipid stabilizers in conditions such as blepharitis, where meibum production is aberrant.

Keywords

HMG-CoA reductase Statin Cholesterol Meibomian gland Blepharitis Dry eye Vascular endothelium 

Notes

Acknowledgements

The immortalized human meibomian gland cell line was provided, with thanks, by Professor David Sullivan, Schepens Eye Research Institute, Boston, MA, USA.

Funding

Professor SL Watson is supported by a Sydney Medical School Foundation fellowship.

This research did not receive any specific grant from funding agencies in the public, commercial, or not for profit sectors.

Compliance with ethical standards

Conflict of interest

KGO and SLW have a patent on topical Atorvastatin as a novel tear film stabilizer.

Ethical approval

The immunolabeling studies were approved by the South Eastern Sydney Local Health District Human Research Committee (HREC ref. no.: 13/359) and adhered to the Tenets of the Declaration of Helsinki.

References

  1. 1.
    Blanco-Colio LM, Tuñón J, Martín-Ventura JL et al (2003) Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 63(1):12–23CrossRefPubMedGoogle Scholar
  2. 2.
    Nicolaides N, Kaitaranta JK, Rawdah TN et al (1981) Meibomian gland studies: comparison of steer and human lipids. Invest Ophthalmol Vis Sci 20(4):522–536PubMedGoogle Scholar
  3. 3.
    Wollensak GME, Mayr A, Baier G et al (1990) Effective methods for the investigation of human tear film proteins and lipids. Graefes Arch Clin Exp Ophthalmol 228(1):78–82CrossRefPubMedGoogle Scholar
  4. 4.
    McCulley JP, Shine W (1997) A compositional based model for the tear film lipid layer. Trans Am Ophthalmol Soc 95:79–93PubMedGoogle Scholar
  5. 5.
    Jester JV, Nicolaides N, Smith RE (1981) Meibomian gland studies: histologic and ultrastructural investigations. Invest Ophthalmol Vis Sci 20(4):537–547PubMedGoogle Scholar
  6. 6.
    Mathers WD, Lane JA (1998) Meibomian gland lipids, evaporation, and tear film stability. Adv Exp Med Biol 438:349–360CrossRefPubMedGoogle Scholar
  7. 7.
    Dougherty JM, McCulley JP (1986) Analysis of the free fatty acid component of meibomian secretions in chronic blepharitis. Invest Ophthalmol Vis Sci 27(1):52–56PubMedGoogle Scholar
  8. 8.
    Cory CC, Hinks W, Burton JL et al (1973) Meibomian gland secretion in the red eyes of rosacea. Br J Dermatol 89(1):25–27CrossRefPubMedGoogle Scholar
  9. 9.
    Shine WE, McCulley JP, Pandya AG (2003) Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res 76(4):417–420CrossRefPubMedGoogle Scholar
  10. 10.
    Albietz JM (2000) Prevalence of dry eye subtypes in clinical optometry practice. Optom Vis Sci 77(7):357–363CrossRefPubMedGoogle Scholar
  11. 11.
    Hom MM, Martinson JR, Knapp LL et al (1990) Prevalence of meibomian gland dysfunction. Optom Vis Sci 67(9):710–712CrossRefPubMedGoogle Scholar
  12. 12.
    Lemp MA, Crews LA, Bron AJ et al (2012) Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea 31(5):472–478CrossRefPubMedGoogle Scholar
  13. 13.
    Patel VD, Watanabe JH, Strauss JA et al (2011) Work productivity loss in patients with dry eye disease: an online survey. Curr Med Res Opin 27(5):1041–1048CrossRefPubMedGoogle Scholar
  14. 14.
    Tseng SC (1985) Staging of conjunctival squamous metaplasia by impression cytology. Ophthalmology 92(6):728–733CrossRefPubMedGoogle Scholar
  15. 15.
    Ooi KG, Wakefield D, Billson FA et al (2015) Efficacy and safety of topical atorvastatin for the treatment of dry eye associated with blepharitis: a pilot study. Ophthalmic Res 54(1):26–33CrossRefPubMedGoogle Scholar
  16. 16.
    Liu S, Hatton MP, Khandelwal P et al (2010) Culture, immortalization, and characterization of human meibomian gland epithelial cells. Invest Ophthalmol Vis Sci 51(8):3993–4005CrossRefPubMedGoogle Scholar
  17. 17.
    Butovich IA, McMahon A, Wojtowicz JC et al (2016) Dissecting lipid metabolism in meibomian glands of humans and mice: an integrative study reveals a network of metabolic reactions not duplicated in other tissues. Biochim Biophys Acta 1861(6):538–553CrossRefPubMedGoogle Scholar
  18. 18.
    Ness GC, Chambers CM (2000) Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity. Proc Soc Exp Biol Med 224(1):8–19CrossRefPubMedGoogle Scholar
  19. 19.
    Feingold KR, Wiley MH, Moser AH et al (1982) De novo sterologenesis in intact primates. J Lab Clin Med 100(3):405–410PubMedGoogle Scholar
  20. 20.
    Fuchs E (2007) Scratching the surface of skin development. Nature 445(7130):834–842CrossRefPubMedGoogle Scholar
  21. 21.
    Endres M, Laufs U, Huang Z et al (1998) Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 95(15):8880–8885CrossRefPubMedGoogle Scholar
  22. 22.
    Li H, Lewis A, Brodsky S et al (2002) Homocysteine induces 3-hydroxy-3-methylglutaryl coenzyme a reductase in vascular endothelial cells. Circulation 105(9):1037CrossRefPubMedGoogle Scholar
  23. 23.
    Shine WE, McCulley JP (1991) The role of cholesterol in chronic blepharitis. Invest Ophthalmol Vis Sci 32(8):2272–2280PubMedGoogle Scholar
  24. 24.
    Dao AH, Spindle JD, Harp BA et al (2010) Association of dyslipidemia in moderate to severe meibomian gland dysfunction. Am J Ophthalmol 150(3):371–375.e371CrossRefPubMedGoogle Scholar
  25. 25.
    Pinna A, Blasetti F, Zinellu A et al (2013) Meibomian gland dysfunction and hypercholesterolemia. Ophthalmology 120(12):2385–2389CrossRefPubMedGoogle Scholar
  26. 26.
    Duman N, Ersoy Evans S et al (2014) Rosacea and cardiovascular risk factors: a case control study. J Eur Acad Dermatol Venereol 28(9):1165–1169CrossRefPubMedGoogle Scholar
  27. 27.
    Hua T-C, Chung P-I, Chen Y-J et al (2015) Cardiovascular comorbidities in patients with rosacea: a nationwide case-control study from Taiwan. J Am Acad Dermatol 73(2):249–254CrossRefPubMedGoogle Scholar
  28. 28.
    Nicolaides N, Flores A, Santos EC et al (1988) The lipids of chalazia. Invest Ophthalmol Vis Sci 29(3):482–486PubMedGoogle Scholar
  29. 29.
    Jameel A, Ooi KGJ, Jeffs NR et al (2013) Statin modulation of human T-cell proliferation, IL-1β and IL-17 production, and IFN-γ T cell expression: synergy with conventional immunosuppressive agents. Int J Inflamm 2013:434586Google Scholar
  30. 30.
    Massingale ML, Li X, Vallabhajosyula M et al (2009) Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea 28(9):1023–1027CrossRefPubMedGoogle Scholar
  31. 31.
    Joshi HNFM, Serajuddin ATM (1999) Differentiation of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors by their relative lipophilicity. Pharm Pharmacol Commun 5:269–271CrossRefGoogle Scholar
  32. 32.
    Wang W, Sasaki H, Chien DS et al (1991) Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: a comparison with corneal penetration. Curr Eye Res 10(6):571–579CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Save Sight InstituteUniversity of Sydney, Sydney Eye Hospital CampusSydneyAustralia
  2. 2.University of SydneySydneyAustralia
  3. 3.University of New South WalesKensingtonAustralia
  4. 4.SydPath, St Vincent’s Pathology DepartmentSt Vincent’s HospitalDarlinghurstAustralia
  5. 5.School of Optometry and Vision ScienceUniversity of New South WalesKensingtonAustralia

Personalised recommendations